Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.35 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198902 | 0.71 | HSP90AA1 (0.38) | SMARCA2SMARCA4CA2CHKA | |
| SCHEMBL31532578 | 0.67 | SMARCA2 (0.33) | SMARCA2SMARCA4 | |
| SCHEMBL17480644 | 0.67 | CYP3A4 (0.38) | SMARCA2SMARCA4 | |
| SCHEMBL24958741 | 0.67 | SMARCA2 (0.33) | SMARCA2SMARCA4 | |
| SCHEMBL9135390 | 0.67 | HSP90AA1 (0.31) | SMARCA2SMARCA4 | |
| SCHEMBL24958740 | 0.66 | DAO (0.41) | SMARCA2SMARCA4 | |
| SCHEMBL25183576 | 0.64 | CDK8 (0.37) | SMARCA2SMARCA4 | |
| SCHEMBL9135386 | 0.64 | NPSR1 (0.37) | SMARCA2SMARCA4 | |
| SCHEMBL24958739 | 0.61 | PKM (0.43) | SMARCA2SMARCA4 | |
| SCHEMBL16705384 | 0.59 | RAB9A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | SMARCA2 1342/4885SMARCA4 1029/4885CA2 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.